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ABSTRACT
Background. In the UK, primary care records are electronic
and require doctors to ascribe disease codes to direct care plans
and facilitate safe prescribing.We investigated factors associated
with coding of chronic kidney disease (CKD) in patients with
reduced kidney function and the impact this has on patient
management.
Methods. We identiﬁed patients meeting biochemical criteria
for CKD (two estimated glomerular ﬁltration rates <60mL/
min/1.73 m2 taken >90 days apart) from 1039 general practi-
tioner (GP) practices in a UK audit. Clustered logistic regression
was used to identify factors associated with coding for CKD and
improvement in coding as a result of the audit process. We
investigated the relationship between coding and ﬁve interven-
tions recommended for CKD: achieving blood pressure targets,
proteinuria testing, statin prescription and ﬂu and pneumococ-
cal vaccination.
Results. Of 256 000 patients with biochemical CKD, 30% did
not have a GP CKD code. Males, older patients, those with
more severe CKD, diabetes or hypertension or those prescribed
statins were more likely to have a CKD code. Among those with
continued biochemical CKD following audit, these same charac-
teristics increased the odds of improved coding. Patients with-
out any kidney diagnosis were less likely to receive optimal care
than those coded for CKD [e.g. odds ratio for meeting blood
pressure target 0.78 (95% conﬁdence interval 0.76–0.79)].
Conclusion. Older age, male sex, diabetes and hypertension are
associated with coding for those with biochemical CKD. CKD
coding is associated with receiving key primary care interven-
tions recommended for CKD. Increased efforts to incentivize
CKD coding may improve outcomes for CKD patients.
Keywords: audit, chronic kidney disease, coding, manage-
ment, primary care
INTRODUCTION
Chronic kidney disease (CKD) has an estimated prevalence in
the UK of 5–7% [1, 2], based on creatinine measurements for
Stages 3–5 disease. The majority of CKD patients are diagnosed
and managed by primary care physicians rather than kidney
specialists in secondary care settings. Early identification of peo-
ple with CKD in primary care, particularly among populations
with risk factors such as diabetes and hypertension, enables
early management of high blood pressure and correction of ad-
verse lifestyle factors. Progression of CKD can be delayed by
such interventions [3] and the implementation of these inter-
ventions can be improved by use of quality improvement (QI)
tools in primary care [4].
In the UK, primary care health records are computerized,
with each condition given a diagnostic Read code to enable
more systematic patient management and appropriate prescrib-
ing. The UKQuality and Outcomes Framework (QOF) [5] is an
ongoing pay-for-performance system that incentivizes aspects
of primary care delivery. Coding for CKD based on
two estimated glomerular filtration rate (eGFR) measurements
<60mL/min/1.73 m2 within 90 days has been incentivized in
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the QOF; however, there is evidence to suggest that this system
does not capture all CKD cases meeting diagnostic criteria. It
has been reported that only 55–70% of patients with biochem-
ical evidence of CKD (Stages 3–5) have an appropriate Read
code in general practitioner (GP) practice databases [6–8].
Practice-level prevalence of coded CKD (as captured in the
QOF) is positively associated with practice prevalence of dia-
betes and cardiovascular disease (CVD) and negatively associ-
ated with social deprivation [9]. The extent of this lack of
coding varies widely by GP practice, even after accounting for
practice-level differences in risk factors such as diabetes [7]. The
QOF registers are also subject to error relating to cases coded as
CKD in the absence of biochemical evidence; recent data sug-
gests that 11% of cases on QOF registers do not fulfil biochem-
ical testing criteria, rising to 36% among those with black
ethnicity [1]. It has further been shown that appropriate coding
of CKD in the primary care electronic record may be associated
with improved blood pressure management and urinary albu-
minuria testing compared with those with uncoded CKD [6].
The National Chronic Kidney Disease Audit (NCKDA) [7]
was set up to audit the testing, identification and management
of CKD in primary care in the UK. The audit capitalized on the
existence of computerized practice records and used an auto-
mated extraction tool that directly extracted data from the elec-
tronic health record with automatic encrypted upload to a
central data safe haven. The first round of data collection
(round 1) provided an initial snapshot of the above outcomes
for the practices enrolled in the audit. Practices were encour-
aged to make use of the electronic QI tools for CKD, which
were developed by the NCKDA team in collaboration with
Informatica Systems as an integral component of the audit. The
QI tools provided practice lists of people with risk factors who
may need testing for CKD, people who may require CKD cod-
ing or coding removal and prompts to support the management
of those with coded CKD. In addition, consultation prompts
alerting clinicians to people with uncoded CKD could be acti-
vated [1]. A second extraction of data was made (round 2) at
least 90 days after round 1 to ascertain the impact of the QI as-
pect of the audit process.
We used individual patient data from the NCKDA to investi-
gate the associations between individual patient characteristics
and coding for CKD among those with biochemical evidence of
CKD based on creatinine measurements. We further sought to
identify the characteristics associated with improvements in
coding status at round 2. Among patients with biochemical evi-
dence of CKD, we then investigated the relationship between
coding and five key markers of primary care management of
CKD [10]: (i) meeting blood pressure targets, (ii) being offered
statins for CVD prevention, (iii) receipt of urinary
albumin:creatinine ratio (ACR) or protein:creatinine ratio
(PCR) testing, (iv) receipt of flu vaccine and (v) receipt of
pneumococcal vaccine (for those with CKD Stages 4–5).
This work will help identify whether there are population
subgroups for whom coding for CKD requires improvement
and whether these same characteristics are associated with a
lack of coding improvement or receipt of primary care interven-
tions aimed at improving patient outcomes.
MATERIALS AND METHODS
Data source and study population
All practices in England and Wales who were current users
of the Informatica Audit Plus software were invited to partici-
pate in NCKDA between March 2015 and July 2016. NCKDA
round 1 data were collected from all GPs in 1039 GP practices
representing an underlying population >18 years of age of
8.24million in England and Wales. Coverage in England and
Wales differed substantially as a result of technical difficulties
and differential use of the software used to extract data for the
NCKDA [1]; final coverage was 76% of practices in Wales
and 9% of practices in England. All Welsh practices had Audit
Plus installed (funded by the National Health Service in Wales)
while in England, practices actively purchased Informatica
Audit Plus software to support better disease management [1].
Data on CKD coding, eGFR test results and relating to CKD
management were extracted for all patients with risk factor cod-
ing for CKD at least 1 year prior to data extraction. A full list of
risk factor codes and full details regarding the study population
are available elsewhere [1]. Practices received e-mail feedback
about the prevalence of biochemical, coded and uncoded CKD
suggesting that they might use the QI software to improve
coding.
Round 2 data were collected from 948 of these practices,
with a median of 8months from round 1 (range 3–20months).
Figure 1 shows patient progress from round 1 to round 2 by
coding status. A total of 65 661 patients with uncoded CKD at
round 1 (i.e. no code for Stages 3–5 CKD, but with biochemical
evidence for CKD) for whom round 2 data confirming bio-
chemical CKD were available were included in an analysis of
coding improvement.
Information about referrals to secondary care was available
through extraction of outpatient referral codes collected at round
1 from the GP record and linkage to outpatient records from
Hospital Episode Statistics (HES) for England (data collected for
the period 1 April 2012–30 June 2016) and NHS Wales
Informatics Statistics (NWIS) (1 January 2012–30 June 2016).
Outcomes
Coding. Coding status for CKD (defined by the presence of a
code for Stages 3–5 CKD) was analysed for 256 433 patients
with biochemical evidence of CKD [two Modification of diet in
renal disease-isotope dilute mass spectrometry (MDRD-IDMS)
eGFR measurements <60mL/min/1.73 m2 at least 90 days
apart]. MDRD IDMSmeasurements incorporating the ethnicity
adjustment were derived from creatinine measurements and
used for this analysis, as the majority of laboratories in the UK
do not report the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) eGFR.
Coding improvement. Among patients with uncoded CKD
at round 1 and for whom round 2 data confirm biochemical
CKD, coding improvers were defined as those who had a code
for Stages 3–5 CKD at round 2.
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Referrals to secondary care. Referral to secondary care is
defined as any nephrologist referral code collected at round 1
from the GP records or any nephrologist outpatient clinic code
held in the HES database (see Supplementary Appendix).
Primary care management of CKD. Blood pressure manage-
ment. Patients were considered to have met blood pressure
targets if they had blood pressure measurements taken in the pre-
vious year and had either (i) systolic blood pressure<130mmHg
and diastolic blood pressure <80mmHg (for those with diabetes
or proteinuria defined as last ACR 70mg/mmol or last PCR
100mg/mmol) or (ii) systolic blood pressure<140mmHg and
diastolic blood pressure <90mmHg (for everyone else). Those
with blood pressure measurements taken >1 year earlier were
not included as meeting targets, regardless of the measurement.
Only the single most recent blood pressure measurement was
available from the GP record.
Statins. As part of a CVD prevention strategy, statin therapy
is recommended for all individuals with CKD Stages 3–5 [11].
We report here on individuals for whom there was any previous
recording of statin prescription collected at round 1 from the
GP record.
Proteinuria testing. It is recommended that testing for protein-
uria be carried out at least once a year for all individuals with CKD
Stages 3–5 (increasing to four times a year for those at Stage 5) [10,
11]. Proteinuria testing was considered as having been undertaken
if patients had an ACR or PCR test collected at round 1 that was
from the previous year or the previous 2years, to provide some in-
sight into the extent of deviation from testing guidelines.
Flu vaccination. Guidelines state that all individuals with
CKD Stages 3–5 should be offered an annual flu vaccination un-
less contraindicated [10]. We report the percentage of patients
receiving this vaccination in the previous year.
Pneumococcal vaccination. For individuals with CKD Stages
4–5, it is additionally recommended that pneumococcal vaccin-
ation be administered unless contraindicated and that individ-
uals should be offered re-vaccination within 5 years [10]. We
report the percentage of patients with Stages 4–5 disease receiv-
ing this vaccination in the previous 5 years.
Among those with uncoded CKD, results are presented sep-
arately for those with and without a urological or renal diagnos-
tic disorder code (a full list of corresponding read codes is
available elsewhere [1]).
Predictors of coding and coding improvement
The following characteristics were considered as potentially
being associated with coding and/or coding improvement:
(i) Age: categorized in 10-year age bands (plus <50- and
90-year groups).
(ii) Index of multiple deprivation (IMD): categorized in ap-
proximate quintiles of the distribution for the study
population, plus an additional category for those with
missing IMD (these are all from Welsh practices; 93%
of Welsh practices did not have any IMD data
available).
(iii) Last known CKD stage: deﬁned by categorizing the last
known eGFR measurement using standard deﬁnitions
[10]: Stage 3a (eGFR 46–59mL/min/1.73 m2), Stage 3b
(eGFR 31–45mL/min/1.73 m2), Stage 4 (eGFR 16–
30mL/min/1.73 m2) and Stage 5 (eGFR <15mL/min/
1.73 m2).
(iv) Diabetes: deﬁned as any previously recorded diagnosis
for diabetes (incentivized by QOF).
(v) Hypertension: deﬁned as any previously recorded date
for hypertension diagnosis (incentivized by QOF).
(vi) Statin prescription: deﬁned as any previously recorded
date on which statins were prescribed.
(vii) Country: indicator for Wales or England.
Statistical methods
Population-averaged logistic generalized estimating equa-
tions (GEE) models were fitted for having coded CKD (among
those with biochemical CKD at round 1) and for coding im-
provement (among those with uncoded biochemical CKD at
round 1 and biochemical CKD at round 2), allowing for cluster-
ing of patients within practices.
The use of five interventions for CKD was summarized
among those with biochemical CKD according to CKD and
renal disorder coding status. Odds ratios (ORs) comparing the
coding groups for each of these management outcomes were
estimated using population-averaged clustered logistic GEE
FIGURE 1: Flow chart showing progress through round 1 (R1) and
round 2 (R2).
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models adjusted for IMD group, sex, age group, country, last
known CKD stage, diabetes, hypertension, CVD and statins (ex-
cept for statins outcome).
RESULTS
Predictors of coding for CKD
A breakdown of coding status by key characteristics is given
in Table 1 for a total of 256 433 patients with Stages 3–5 bio-
chemical CKD, among which 78 156 (30%) did not have a read
code for CKD. There was considerable interpractice variation in
the proportion of biochemical CKD cases that were coded,
ranging from 4 to 100%.
Being male, being older, having later stage CKD, lower IMD
(more deprived), diabetes or hypertension and being offered
statins were all associated with increased odds of coding in un-
adjusted analyses. In a mutually adjusted analysis, all these asso-
ciations remained except for IMD (Table 1). Belonging to an
English practice rather than a Welsh practice also seemed to in-
crease the odds of coding in both the unadjusted and adjusted
analyses. There was evidence that the difference between males
and females was only present in Wales {multivariable OR for
males in Wales 1.11 [95% confidence interval (CI) 1.07–1.14];
in England, multivariable OR 1.01 (95% CI 0.99–1.04); P-value
for interaction<0.0005}.
Around half of those with uncoded Stage 5 CKD (164/317)
also had a renal disorder code (Table 2). Of the 153 who did
not, 45 had either a dialysis or a transplant code, and a further
70 had a nephrologist referral code (either in the audit data or
HES data). This left 38/3254 (1%) patients with biochemical evi-
dence of Stage 5 CKD who were not coded for CKD, had no
other renal code and who also had no referral, dialysis or trans-
plant code.
Predictors of coding improvement at round 2
Among those with uncoded biochemical CKD at round 1
who also had biochemical evidence of CKD at round 2, 5211 pa-
tients [of 54 000 (9.7%)] were found to have been coded at
round 2 (Table 3).
After adjusting for other factors, those <60 years of age had
a 15–20% reduction in the odds of coding improvement
Table 1. Coding for CKD by patient characteristics among those with biochemical evidence of CKD
n with biochemical
CKD at round 1
% of these who are
coded for CKD
Univariable OR for
coding (95% CI)
Multivariablea
OR for coding (95% CI)
Sex
Female 152 194 68.8 1 1
Male 104 239 70.6 1.09 (1.06–1.11) 1.04 (1.02–1.07)
Age (years)
<50 5371 57.7 0.82 (0.77–0.87) 0.82 (0.78–0.88)
50–59 12 612 55.9 0.79 (0.76–0.82) 0.86 (0.83–0.89)
60–69 39 520 62.1 1 1
70–79 82 776 69.7 1.38 (1.34–1.42) 1.23 (1.20–1.27)
80–89 90 209 73.9 1.69 (1.64–1.75) 1.37 (1.32–1.41)
90 25 945 74.2 1.72 (1.64–1.80) 1.34 (1.28–1.40)
IMDb
<10 000 41 051 71.4 1 1
10 000–14 999 28 079 71.2 0.98 (0.95–1.02) 1.00 (0.97–1.04)
15 000–19 999 30 222 70.4 0.95 (0.92–0.99) 0.98 (0.94–1.02)
20 000–24 999 31 815 70.1 0.94 (0.91–0.97) 0.99 (0.95–1.02)
25 000 40 230 70.1 0.95 (0.91–0.99) 1.01 (0.97–1.05)
Missing 85 036 67.2 0.86 (0.78–0.95) 1.09 (0.96–1.23)
Last known CKD stagec
Stage 3a 160 100 60.8 1 1
Stage 3b 75 855 82.5 3.01 (2.90–3.12) 2.71 (2.62–2.80)
Stage 4 17 224 89.7 5.64 (5.25–6.06) 5.03 (4.70–5.38)
Stage 5 3254 90.3 5.94 (5.22–6.77) 5.81 (5.13–6.58)
Diabetes
No 187 716 67.5 1 1
Yes 68 717 75.2 1.45 (1.41–1.49) 1.11 (1.08–1.14)
Hypertension
No 74 817 59.2 1 1
Yes 181 616 73.8 1.83 (1.79–1.87) 1.50 (1.47–1.53)
Statin offered
No 84 885 62.0 1 1
Yes 171 548 73.3 1.64 (1.60–1.67) 1.38 (1.35–1.40)
Country
Wales 85 308 67.1 1 1
England 171 125 70.7 1.25 (1.12–1.40) 1.42 (1.18–1.71)
aSimultaneous adjustment for all characteristics in the table.
bLow IMD rank corresponds to higher deprivation.
cBased on last eGFR measurement. Stage 3a: eGFR 46–59mL/min/1.73 m2; Stage 3b: eGFR 31–45mL/min/1.73 m2; Stage 4: eGFR 16–30mL/min/1.73 m2; Stage 5: eGFR <15mL/min/
1.73 m2.
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compared with those 60 years of age, although those aged
90 years of age also had a 15% reduction in the odds of coding
improvement compared with those 60–69 years of age [OR 0.86
(95% CI 0.79, 0.95)] (Table 3). Those with CKD Stages 3b–5 all
had a 1.5- to 2-fold increase in the odds of coding compared
with those with biochemical evidence for CKD Stage 3a.
Furthermore, there was evidence of higher odds of coding im-
provement among males and those with diabetes, hypertension
and on statins. There was no evidence of a difference in im-
provement by IMD.
Associations of coding with CKD management
Receipt of all primary care management interventions was
highest in those who were coded for CKD (Table 4). The odds
of receiving each intervention were greatest in those with coded
CKD; the odds of intervention were comparatively reduced
among those with uncoded CKD and a renal disorder code (ex-
cept for statins, where the adjusted odds were similar to those
with coded CKD), and reduced even further for those with
uncoded CKD and no renal disorder code.
Blood pressure targets had only been met in the previous
year in50% of patients with coded CKD; the odds of meeting
the target were even lower in those with uncoded CKD, with a
15% reduction in those with a renal code and a 20% reduction
in those without a renal disease code. Proteinuria testing was
also low, at 50% of coded CKD patients in the previous year;
this was considerably lower in those with uncoded CKD, with
an50% and 80% reduction in odds for those with and without
renal codes, respectively. Around 70% of those patients with
coded CKD had been offered a statin at some time in the past,
with substantially reduced odds for those with uncoded CKD
and no renal disease code. There was an20% reduction in the
odds of receiving both vaccinations for those with uncoded
CKD and a renal code compared with those with coded CKD,
and a 25% reduction in odds for those with uncoded CKD and
no renal code.
Referrals to secondary care
Referrals recorded on either the GP record or HES databases
accounted for 27.9% of those with uncoded CKD at round 1
with a renal code but only 5.3% of those with uncoded CKD
and no renal code (compared with 19.0% of those with coded
CKD).
DISCUSSION
Main findings
Younger patients, females and those without major co-
morbidities (diabetes, hypertension) who have biochemical evi-
dence of CKD are least likely to have a CKD (Stages 3–5) code in
their primary care record. Patients with biochemical CKD with-
out a CKD code were less likely to be offered a statin, receive flu
and pneumococcal vaccination and have their blood pressure
controlled to target or have undergone proteinuria testing. Those
who have biochemical evidence of CKD and a renal code were
more likely to have received some interventions, but not to the
same level as people with biochemical CKDwho were coded.
Main findings in context
Among the 256 433 cases with biochemical evidence of CKD
at round 1 of the national CKD audit, only 70% (178 277) are
Table 3. Coding improvement among those with biochemical evidence of
CKD at R1 (uncoded) and R2 of the National CKD Audit
n with biochemical
evidence of CKD
at R1 (uncoded)
and R2
% of these
coded at R2
Multivariablea
OR for coding
improvement at
R2 (95% CI)
Sex
Female 32 661 9.0 1
Male 21 339 10.7 1.14 (1.09–1.19)
Age (years)
<50 1507 8.2 0.83 (0.72–0.97)
50–59 3636 7.5 0.85 (0.78–0.94)
60–69 10 243 9.7 1
70–79 17 844 10.4 1.04 (0.99–1.10)
80–89 16 537 9.6 0.96 (0.90–1.02)
90 4233 9.2 0.86 (0.79–0.95)
IMDb
<10 000 7481 11.7 1
10 000–14 999 5286 11.8 1.01 (0.92–1.12)
15 000–19 999 5816 13.0 0.97 (0.87–1.07)
20 000–24 999 6514 10.8 0.93 (0.85–1.02)
25 000 8088 10.9 0.94 (0.87–1.03)
Missing 20 815 6.6 0.85 (0.63–1.16)
Last known CKD stagec
Stage 3a 42 405 8.7 1
Stage 3b 10 085 12.5 1.50 (1.42–1.59)
Stage 4 1302 16.9 2.02 (1.78–2.30)
Stage 5 208 13.9 1.53 (1.08–2.17)
Diabetes status
No 41 934 9.0 1
Yes 12 066 11.8 1.21 (1.15–1.28)
Hypertension status
No 20 784 8.1 1
Yes 33 216 10.6 1.24 (1.17–1.31)
Statin offered
No 21 850 8.8 1
Yes 32 150 10.2 1.08 (1.03–1.13)
Country
Wales 20 917 6.7 1
England 33 083 11.5 1.21 (0.81–1.79)
R1, round 1; R2, round 2.
aSimultaneous adjustment for all characteristics in the table.
bLow IMD rank corresponds to higher deprivation.
cBased on the last eGFR measurement at R1. Stage 3a: eGFR 46–59mL/min/1.73 m2;
Stage 3b: eGFR 31–45mL/min/1.73 m2; Stage 4: eGFR 16–30mL/min/1.73 m2; Stage 5:
eGFR <15mL/min/1.73 m2.
Table 2. Percentage of coding for renal disorder by CKD coding status and
stage among those with biochemical evidence of CKD at round 1 of the
National CKD Audit
CKD coded CKD not coded
Last known
CKD stagea
n % with renal
disorder code
n % with renal
disorder code
Stage 3a 97 352 13.7 62 748 6.2
Stage 3b 62 543 19.3 13 312 12.0
Stage 4 15 445 34.6 1779 27.7
Stage 5 2937 59.1 317 51.7
aBased on last eGFR measurement. Stage 3a: eGFR 46–59mL/min/1.73 m2; Stage 3b:
eGFR 31–45mL/min/1.73 m2; Stage 4: eGFR 16–30mL/min/1.73 m2; Stage 5: eGFR
<15mL/min/1.73 m2.
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included on the QOF register as CKD Stages 3–5. This compares
to 72% reported by Jain et al. [6] in a sample of similar size from
2005 to 2009. Although broadly similar, some of the difference
could be explained by the definitions of biochemical CKD used
(we use two eGFRs at least 3months apart, versus their two
measurements 7 days apart) and our use of re-calculated eGFRs.
Among those patients with biochemical evidence of CKD,
males, older patients, those with lower eGFR (more severe CKD
stage), diabetes, hypertension or receiving statins and those in
English practices had increased odds of being coded for CKD.
Another study previously reported similar relationships with sex
and co-morbidities, but not with age [12]. Our results suggest that
even for patients with the same CKD stage and comorbidities,
younger patients have reduced odds of coding compared with
older patients. Furthermore, we have shown that these same char-
acteristics (except country) were associated with coding improve-
ment following audit among those patients with uncoded
biochemical CKD at round 1 who still had evidence of biochem-
ical CKD at round 2. Although others have demonstrated that QI
tools can be useful in improving intervention outcomes [13], such
studies have taken a more direct approach to improve specific
interventions, such as blood pressure control, rather than through
coding improvements, whichmay bemore wide-reaching.
Our findings on management interventions for patients with
coded CKD in primary care are also broadly similar to those re-
ported elsewhere [14, 15], but we have also demonstrated the
positive relationship between coding and patient management.
Interpretation and implication
There are many reasons why an individual with biochemical
evidence of CKD may not have a corresponding code, including
uncertainty about guidelines for testing and diagnosis and con-
cern about medicalizing a natural ageing process [15]. However,
the relevance of the absence of coding lies in its potential impact
on a range of patient measures in primary care. Here, this is sub-
stantiated by the reported differences in the application of key
management interventions between coded and uncoded groups
with biochemical CKD. Among those with uncoded CKD, hav-
ing a renal disorder code is associated with higher application of
all these interventions, though not to the same level as those
with a CKD code. We examined the possibility that the observed
differences are, at least in part, due to differences in recording of
these interventions and whether those with renal disorder codes
can be managed in secondary rather than primary care, with a
corresponding lack of recording on GP databases. Investigation
of referrals to secondary care suggests that although the differ-
ence in interventions in patients with coded CKD and those
with uncoded CKD and a renal disorder may be explained in
part by differences in referrals, there is no evidence that patients
without a CKD or a renal disorder code are receiving interven-
tions in secondary care. However, it is also possible that some
referrals were not captured here, for example, for joint specialist
outpatient clinics, which may be coded under the non-
nephrology speciality code in HES (e.g. joint diabetic–renal spe-
cialist clinic or joint urology–renal clinic).
Our findings suggest that practices and local health author-
ities should take a more active approach to ensuring CKD cod-
ing and resultant patient review for those with CKD and that
implementation is encouraged using active QI techniques. In
the UK, this is of particular importance, as the renal QOF indi-
cators have now been retired [16].
Strengths and limitations
We used data from a large, population-based study to inves-
tigate relationships between coding, patient characteristics and
care. Although large and with good coverage of Welsh practices
(76%), the study includes only 9% of English GP practices. It is
likely that practices with higher ethnic minorities are under-
represented in this sample (in England, the non-white popula-
tion is 9.1%, compared with 4.4% in Wales [17]). Previous
work has suggested that CKD prevalence varies across ethnic
minorities [18], but also that management outcomes may be
reduced in these minority subgroups [19]. Furthermore, partici-
pating English practices chose to install the audit software and
therefore were more likely to have an interest in QI. In light of
this, for England, the underlying proportion of uncoded bio-
chemical CKD cases may be even higher than we report and
management outcomes may be lower in some or all of the
groups of patients with CKD.
Limitations of the audit include the use of routinely collected
clinical data. There will inevitably be inaccuracies in the clinical
data set and it is likely that there will be underrecording of at
least some morbidities; however, underrecording would mean
that the GP also is not aware of the respective morbidity.
The ‘missingness’ in hypertension, diabetes and statin
Table 4. Management outcomes for those with biochemical evidence of
CKD at round 1, by coding status
Coded CKD Uncoded CKD
with renal
disorder code
Uncoded CKD
without renal
disorder code
n 178 277 6176 71 980
Met blood pressure target in past yeara
% achieving outcome 51.5 41.7 46.8
Adjusted OR (95% CI)b 1 0.83 (0.78–0.87) 0.78 (0.76–0.79)
Statins offered
% achieving outcome 70.5 69.2 57.8
Adjusted OR (95% CI)c 1 1.04 (0.97–1.11) 0.69 (0.67–0.71)
ACR/PCR test in the past year
% achieving outcome 49.7 32.7 15.9
Adjusted OR (95% CI)d 1 0.50 (0.45–0.55) 0.20 (0.18–0.22)
ACR/PCR test in the past 2 years
% achieving outcome 73.8 49.4 25.1
Adjusted OR (95% CI)d 1 0.35 (0.32–0.39) 0.12 (0.11–0.13)
Flu vaccination in the past year
% achieving outcome 79.3 72.9 69.6
Adjusted OR (95% CI)b 1 0.83 (0.77–0.88) 0.75 (0.73–0.77)
Pneumococcus vaccination in the past 5 years, Stages 4–5 only (based on last
eGFR)e
% achieving outcome 16.1 15.5 11.3
Adjusted OR (95% CI)b 1 0.79 (0.63–1.00) 0.73 (0.62–0.86)
aMeasurements taken in the past year and systolic blood pressure (SBP) <130mmHg
and diastolic blood pressure (DBP) <80mmHg (for those with diabetes or proteinuria)
or SBP <140mmHg and DBP <90mmHg for everyone else.
bAdjusted for IMD group, sex, age group, country, last known CKD stage, diabetes,
hypertension, CVD and statins offered.
cAdjusted for sex, age group, last known CKD stage, hypertension and CVD (due to
model convergence).
dAdjusted for age group and last known CKD stage only (due to model convergence).
eNumbers in Stages 4–5 in each coding category: coded CKD, n¼ 19 076; uncoded CKD
with renal code, n¼ 755; uncoded CKD without renal code, n¼ 1739.
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prescriptions is not known, since this would occur where there
is an absence of a recorded date, making it indistinguishable
from individuals without these events. However, as recording of
hypertension and diabetes has been incentivized by the QOF
through a number of measures, there is little reason to assume
that a majority of cases would have been missed.
CONCLUSIONS
Electronic QI initiatives, which alert practitioners to uncoded
CKD cases, with in-consultation prompts and patient lists
requiring action, produce a small but important improvement
in coding. However, this improvement tends to be focused on
older patients and those with well-established risk factors for
CKD. Further efforts to improve coding for younger patients
who have much to gain from regular CKD review, blood pres-
sure and CVD risk management are needed.
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